

Liver Degenerative Disease

REFERENCES

AMA. The American Medical Association Encyclopedia of Medicine 1989. New York: Random House.

Anon. Holistic Health Encyclopedia 2002. Oakford, PA: Telstar Innovations.

Attri, S., Rana, S.V., Vaiphie, K., Katyal, R., Sodhi, C.P., Kanwar, S., Singh, K. Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. *Indian J. Exp. Biol.* 2001 May; 39(5): 436-40.

Bergasa, N.V. Itching in Liver Disease 2002 Sep; New York: Columbia University.

Berson, A., De Beco, V., Letteron, P., Robin, M.A., Moreau, C., El Kahwaji, J., Verthier, N., Feldmann, G., Fromenty, B., Pessayre, D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. *Gastroenterology* 1998 Apr; 114(4): 764-74.

Biewenga, G.P., Haenen, G.R., Bast, A. The pharmacology of the antioxidant lipoic acid. *Gen. Pharmacol.* 1997 Sep; 29(3): 315-31.

Bosisio, E., Benelli, C., Pirola, O. Effect of the flavanolignans of *Silybum marianum* L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. *Pharmacol. Res.* 1992 Feb-Mar; 25(2): 147-54.

Braillon, A., Capron, J.P., Herve, M.A., Degott, C., Quenum, C. Liver in obesity. *Gut* 1985 Feb; 26(2): 133-9

Brewer, G.J., Fink, J.K., Hedera, P. Diagnosis and treatment of Wilson's disease. *Semin. Neurol.* 1999; 19(3): 261-70.

Britton, R.S., Bacon, B.R. Role of free radicals in liver diseases and hepatic fibrosis. *Hepatogastroenterology* 1994 Aug; 41(4): 34-8.

Chalasani, N., Gitlin, N. Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. *Am. J. Gastroenterol.* 1996 Jun; 91(6): 1266-8.

Chern, C.L., Huang, R.F., Chen, Y.H., Cheng, J.T., Liu, T.Z. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. *Biomed. Pharmacother.* 2001 Oct; 55(8): 434-42

Day, C.P., Yeaman, S.J. The biochemistry of alcohol-induced fatty liver. *Biochem. Biophys. Acta* 1994 Nov 17; 1215(1-2): 33-48.

Deulofeu, R., Pares, A., Rubio, M., Gasso, M., Roman, J., Gimenez, A., Varela-Moreiras, G., Caballeria, J., Ballesta, A.M., Mato, J.M., Rodes, J. S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. *Clin. Sci.* 2000 Oct; 99(4): 315-20.

Feher, J., Vereckei, A., Lengyel, G. Role of free-radical reactions in liver diseases. *Acta Physiol. Hung.* 1992; 80(1-4): 351-61.

Fernandez, E., Pallini, R., Lauretti, L., La Marca, F., Scogna, A., Rossi, G.F. Motonuclear changes after cranial nerve injury and regeneration. *Arch. Ital. Biol.* 1997 Sep; 135(4): 343-51.

Garg, M.C., Bansal, D.D. Protective antioxidant effect of vitamins C and E in streptozotocin induced diabetic rats. *Indian J. Exp. Biol.* 2000 Feb; 38(2): 101-4.

Genova, M.L., Bonacorsi, E., D'Aurelio, M., Formiggini, G., Nardo, B., Cuccomarino, S., Turi, P., Pich, M.M., Lenaz, G., Bovina, C. Protective effect of exogenous coenzyme Q in rats subjected to partial hepatic ischemia and reperfusion. *Biofactors* 1999; 9(2-4): 345-9.

Glanze, W.D., Ed. Mosby Medical Encyclopedia, Revised Edition 1996. St. Louis, MO: C.V. Mosby.

Gumina, G., Song, G.Y., Chu, C.K. Advances in antiviral agents for hepatitis B virus. *Antivir. Chem. Chemother.* 2001; 12(Suppl. 1): 93-117.

Hazai, E., Monostory, K., Bakos, A., Zacher, G., Vereczkey, L. About paracetamol again. *Orv. Hetil.* 2001 Feb 18; 142(7): 345-9 (in Hungarian).

Kato, M., Miwa, Y., Tajika, M., Hiraoka, T., Muto, Y., Moriwaki, H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. *Intern. Med.* 1998 May; 37(5): 429-34.

Khanna, S., Atalay, M., Laaksonen, D.E. et al. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. *J. Appl. Physiol.* 1999 Apr; 86(4): 1191-6.

Lammert, F., Busch, N., Matern, S. Clinical aspects and therapy of viral hepatitis. *Chirurg* 2000 Apr; 71(4): 381-8 (in German).

Lieber, C.S. Prevention and treatment of liver fibrosis based on pathogenesis. *Alcohol Clin. Exp. Res.* 1999 May; 23(5): 944-9.

Lykkesfeld, J. et al. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with R alpha lipoic acid supplementation. *FASEB J.* 1998; 12: 1183-9.

Ma, X., Zhao, J., Lieber, C.S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. *J. Hepatol.* 1996 May; 24(5): 604-13.

Malik, A.H., Lee, W.M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. *Ann. Intern. Med.* 2000 May 2; 132(9): 723-31.

Mayerat, C., Mantegani, A., Spertini, F., Frei, P.C. Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B. *Eur. J. Clin. Microbiol. Infect. Dis.* 1999 Dec; 18(12): 871-8.

Mirossay, L., Mojzis, J., Sallingova, Z. et al. Gastroprotective effect of malotilate in indomethacin- and ethanol-induced gastric mucosal damage. *Physiol. Res.* 1996; 45(5): 405-11.

Mydlik, M., Derzsiova, K., Racz, O., Sipulova, A., Boldizsar, J., Lovasova, E., Hribikova, M. Vitamin E as an antioxidant agent in CAPD patients. *Int. J. Artif. Organs* 2002 May; 25(5): 373-8.

Navder, K.P., Baraona, E., Lieber, C.S. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. *J. Nutr.* 1997 Sep; 127(9): 1800-6.

NIDA. Hepatitis C. NIDA Community Drug Alert Bulletin 2002 Feb 21. Bethesda, MD: National Institute on Drug Abuse/National Institutes of Health/Department of Health and Human Services.

NIDDK. Cirrhosis of the Liver 2000 Jan. NIH Publ. No. 00-1134. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health.

Nidus. What are the primary treatments for cirrhosis? Well-Connected Report: Cirrhosis 1999 Mar. New York: Nidus Information Services (www.well-connected.com).

Ou, J.H.J. Viral hepatitis and its prevention. *Infection Control Today Magazine* 2002. Phoenix, AZ: Virgo Publishing.

Paradies, G., Petrosillo, G., Gadaleta, M.N., Ruggiero, F.M. The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. *FEBS Lett.* 1999 Jul 9; 454(3): 207-9.

Pniachik, J., Baraona, E., Zhao, J., Lieber, C.S. Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. *J. Lab. Clin. Med.* 1999 Apr; 133(4): 342-8.

Rao, K.V., Qureshi, I.A. Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyper-ammonemia: prevention by acetyl-L-carnitine. *Neuropharmacology* 1999 Mar; 38(3): 383-94.

Ryhanen, L., Stenback, F., Ala-Kokko, L., Savolainen, E.R. The effect of malotilate on type III and type IV collagen, laminin and

fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat. *J. Hepatol.* 1996 Feb; 24(2): 238-45.

Sakaguchi, S., Iizuka, Y., Furusawa, S., Tanaka, Y., Takayanagi, M., Takayanagi, Y. Roles of selenium in endotoxin-induced lipid peroxidation in the rats liver and in nitric oxide production in J774A.1 cells. *Toxicol. Lett.* 200 Dec 20; 118(1-2): 69-77.

Shimazu, Y. An experimental and clinical study of energy-protein metabolism and host defense-repair mechanism in postoperative period-a significance of administration of branched chain amino acid. *Nippon Geka Gakkai Zasshi* 1990 Oct; 91(10): 1534-47 (in Japanese).

Sonnenbichler, J., Goldberg, M., Hane, L., Madubunyi, I., Vogl, S., Zetl, I. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. *Biochem. Pharmacol.* 1986a Feb 1; 35(3): 538-41.

Sonnenbichler, J., Zetl, I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. *Prog. Clin. Biol. Res.* 1986b; 213: 319-31.

Strickland, D.K. Hepatitis C. *eMed. J.* 2002 Jan 16 (<http://www.emedicine.com/ped/topic979.htm>).

Takase, S., Matsuda, Y., Yasuhara, M., Takada, A. Effects of malotilate treatment on alcoholic liver disease. *Alcohol* 1989 May-Jun; 6(3): 219-22.

Teranishi, M., Karbowski, M., Kurono, C., Nishizawa, Y., Usukura, J., Soji, T., Wakabayashi, T. Effects of coenzyme Q10 on changes in the membrane potential and rate of generation of reactive oxygen species in hydrazine- and chloramphenicol-treated rat liver mitochondria. *Arch. Biochem. Biophys.* 1999 Jun 1; 366(1): 157-67.

Valenzuela, A., Aspillaga, M., Vial, S., Guerra, R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. *Planta Med.* 1989 Oct; 55(5): 420-2.

Vineis, P., Esteve, J., Terracini, B. Bladder cancer and smoking in males: types of cigarettes, age at start, effect of stopping and interaction with occupation. *Int. J. Cancer* 1984 Aug 15; 34(2): 165-70.

Vineis, P., Magnani, C. Occupation and bladder cancer in males: a case-control study. *Int. J. Cancer* 1985 May 15; 35(5): 599-606.

Wallace, L.A., Pellizzari, E.D., Hartwell, T.D., Davis, V., Michael, L.C., Whitmore, R.W. The influence of personal activities on exposure to volatile organic compounds. *Environ. Res.* 1989 Oct; 50(1): 37-55.

Wolf, D.C. Cirrhosis. *eMed. J.* 2001 Sep 6; 2(9) (<http://www.emedicine.com/med/topic3183.htm>).

Yang, S.Q., Lin, H.Z., Lane, M.D., Clemens, M., Diehl, A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. *Proc. Natl. Acad. Sci. U.S.A.* 1997 Mar 18; 94(6): 2557-62.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension®

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.